Clinical Trials in Arizona

Showing 6981-7000 of 16,770 trials

A Study of FT-7051 in Men With MCRPC

NCT04575766

This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051 and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK), preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic castration-resistant prostate cancer who have progressed despite prior therapy and had been treated with at least one potent anti-androgen therapy. The starting dose, 25 mg once daily (QD), of FT-7051 administered discontinuously (21 days on/7 days off) in 28-day cycles.

Metastatic Castration-resistant Prostate Cancer

Novo Nordisk A/S25 participantsStarted Dec 2020

Scottsdale, Arizona, United States • Aurora, Colorado, United States • Chicago, Illinois, United States +5 more locations

COMPLETEDPhase 331 miles

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03654274

The purpose of this study is to evaluate the long-term efficacy and safety of relugolix 40 milligram (mg) once daily co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) for up to 104 weeks on endometriosis-associated pain in participants who previously completed a 24-week treatment period in one of the parent studies (MVT-601-3101 or MVT-601-3102).

Endometriosis

Myovant Sciences GmbH802 participantsStarted May 2018

Andalusia, Alabama, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +166 more locations

A Study of FT-7051 in Men With MCRPC

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

Find Trials by Condition in Arizona

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

Decision Aids to Improve Knowledge in Patients With Prostate Cancer

To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

Look AHEAD: Action for Health in Diabetes

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease

A Study of PRN1008 in Patients With Pemphigus

Zalutumumab in Non-curable Patients With SCCHN

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion

Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3

ADVM-022 Intravitreal Gene Therapy for Wet AMD

Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

Family Health History in Diverse Care Settings (FHH)

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)